81030 Utilizing a synergistic drug combination to target relapsed/refractory FLT3 mutant AML

por Jones, LaQuita, Melgar, Katelyn, Hoyt, Scott, Wunderlich, Mark, O’Brien, Eric, Perentesis, John, Thomas, Craig, Starczynowski, Daniel
Publicado 2021

Improved chemotherapy modeling with RAG-based immune deficient mice

por Wunderlich, Mark, Manning, Nicole, Sexton, Christina, Sabulski, Anthony, Byerly, Luke, O’Brien, Eric, Perentesis, John P., Mizukawa, Benjamin, Mulloy, James C.
Publicado 2019

PD-1 Inhibition Enhances Blinatumomab Response in a UCB/PDX Model of Relapsed Pediatric B-Cell Acute Lymphoblastic Leukemia

por Wunderlich, Mark, Manning, Nicole, Sexton, Christina, O’Brien, Eric, Byerly, Luke, Stillwell, Cody, Perentesis, John P., Mulloy, James C., Mizukawa, Benjamin
Publicado 2021

Antitumor immunity augments the therapeutic effects of p53 activation on acute myeloid leukemia

por Hayashi, Yasutaka, Goyama, Susumu, Liu, XiaoXiao, Tamura, Moe, Asada, Shuhei, Tanaka, Yosuke, Fukuyama, Tomofusa, Wunderlich, Mark, O’Brien, Eric, Mizukawa, Benjamin, Yamazaki, Satoshi, Matsumoto, Akiko, Yamasaki, Satoshi, Shibata, Tatsuhiro, Matsuda, Koichi, Sashida, Goro, Takizawa, Hitoshi, Kitamura, Toshio
Publicado 2019

HDAC1 and HDAC6 are essential for driving growth in IDH1 mutant glioma

por Garrett, Matthew C., Albano, Rebecca, Carnwath, Troy, Elahi, Lubayna, Behrmann, Catherine A., Pemberton, Merissa, Woo, Daniel, O’Brien, Eric, VanCauwenbergh, Brett, Perentesis, John, Shah, Sanjit, Hagan, Matthew, Kendler, Ady, Zhao, Chuntao, Paranjpe, Aditi, Roskin, Krishna, Kornblum, Harley, Plas, David R., Lu, Q. Richard
Publicado 2023

miR-196b target screen reveals mechanisms maintaining leukemia stemness with therapeutic potential

por Meyer, Sara E., Muench, David E., Rogers, Andrew M., Newkold, Tess J., Orr, Emily, O’Brien, Eric, Perentesis, John P., Doench, John G., Lal, Ashish, Morris, Patrick J., Thomas, Craig J., Lieberman, Judy, McGlinn, Edwina, Aronow, Bruce J., Salomonis, Nathan, Grimes, H. Leighton
Publicado 2018

IMPDH inhibition activates TLR‐VCAM1 pathway and suppresses the development of MLL‐fusion leukemia

por Liu, Xiaoxiao, Sato, Naru, Yabushita, Tomohiro, Li, Jingmei, Jia, Yuhan, Tamura, Moe, Asada, Shuhei, Fujino, Takeshi, Fukushima, Tsuyoshi, Yonezawa, Taishi, Tanaka, Yosuke, Fukuyama, Tomofusa, Tsuchiya, Akiho, Shikata, Shiori, Iwamura, Hiroyuki, Kinouchi, Chieko, Komatsu, Kensuke, Yamasaki, Satoshi, Shibata, Tatsuhiro, Sasaki, Atsuo T, Schibler, Janet, Wunderlich, Mark, O'Brien, Eric, Mizukawa, Benjamin, Mulloy, James C, Sugiura, Yuki, Takizawa, Hitoshi, Shibata, Takuma, Miyake, Kensuke, Kitamura, Toshio, Goyama, Susumu
Publicado 2022

MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199

por Benito, Juliana M., Godfrey, Laura, Kojima, Kensuke, Hogdal, Leah, Wunderlich, Mark, Geng, Huimin, Marzo, Isabel, Harutyunyan, Karine G., Golfman, Leonard, North, Phillip, Kerry, Jon, Ballabio, Erica, Chonghaile, Triona Ní, Gonzalo, Oscar, Qiu, Yihua, Jeremias, Irmela, Debose, LaKiesha, O’Brien, Eric, Ma, Helen, Zhou, Ping, Jacamo, Rodrigo, Park, Eugene, Coombes, Kevin R., Zhang, Nianxiang, Thomas, Deborah A., O’Brien, Susan, Kantarjian, Hagop M., Leverson, Joel D., Kornblau, Steven M., Andreeff, Michael, Müschen, Markus, Zweidler-McKay, Patrick A., Mulloy, James C., Letai, Anthony, Milne, Thomas A., Konopleva, Marina
Publicado 2015